文献速递慢性肾脏病血液净化与透析

糖尿病合并慢性肾脏病患者的降糖药物使用

Use of Glucose-Lowering Agents in Diabetes and CKD.
PubMed 文献 · Kidney Int Rep · 2022-09-29

综述指出糖尿病是肾衰竭最常见病因,合并CKD者心血管病尤其心衰和死亡风险显著升高。血糖目标应个体化,早期CKD可约7%,晚期可放宽。SGLT2抑制剂和GLP-1受体激动剂改善肾心结局,已成为指南导向药物治疗的一部分。

要点

  • 糖尿病合并CKD患者心衰和死亡风险显著升高。
  • HbA1c目标应个体化,早期CKD可约7%,晚期常可放宽。
  • SGLT2抑制剂和GLP-1受体激动剂改善肾心结局,已纳入指南导向治疗。

核心结论

  • 糖尿病合并CKD患者使用SGLT2抑制剂和GLP-1受体激动剂可改善肾脏和心脏结局,与HbA1c目标无关,已成为该高危人群指南导向药物治疗的一部分。

研究设计与样本

  • 综述,检索范围原文未报告。

主要发现

  • 糖尿病是全世界肾衰竭最常见的原因。
  • 糖尿病合并CKD患者心血管疾病尤其心衰和死亡风险显著升高。
  • 胰岛素抵抗是CKD早期改变,常因高血压、肥胖、持续慢性炎症和氧化应激而加重。
  • 中重度CKD的糖尿病管理需特殊考虑,因葡萄糖和胰岛素稳态改变及降糖治疗代谢改变。
  • 肾衰竭和开始透析增加管理复杂性,进一步限制治疗选择并易致低血糖和高血糖。

关键数值与推荐

  • 血糖目标应个体化,考虑CKD严重程度、大血管和微血管并发症及预期寿命。
  • 早期CKD一般HbA1c目标约7%可能合适,晚期常可放宽目标。
  • SGLT2抑制剂和GLP-1受体激动剂改善糖尿病合并CKD患者肾脏和心脏结局,与HbA1c目标无关。

临床怎么用

  • 糖尿病合并CKD患者的优化管理需要跨医疗专科和学科协作。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diabetes is the most common cause of kidney failure worldwide. Patients with diabetes and chronic kidney disease (CKD) are also at markedly higher risk of cardiovascular disease, particularly heart failure (HF), and death. Through the processes of gluconeogenesis and glucose reabsorption, the kidney plays a central role in glucose homeostasis. Insulin resistance is an early alteration observed in CKD, worsened by the frequent presence of hypertension, obesity, and ongoing chronic inflammation, and oxidative stress. Management of diabetes in moderate to severe CKD warrants special consideration because of changes in glucose and insulin homeostasis and altered metabolism of glucose-lowering therapies. Kidney failure and initiation of kidney replacement therapy by dialysis adds to management complexity by further limiting therapeutic options, and predisposing individuals to hypoglycemia and hyperglycemia. Glycemic goals should be individualized, considering CKD severity, presence of macrovascular and microvascular complications, and life expectancy. A general hemoglobin A1c (HbA1c) goal of approximately 7% may be appropriate in earlier stages of CKD, with more relaxed targets often appropriate in later stages. Use of sodium glucose cotransporter2 (SGLT2) inhibitors and glucagon like peptide-1 receptor agonists (GLP-1RAs) meaningfully improves kidney and heart outcomes for patients with diabetes and CKD, irrespective of HbA1c targets, and are now part of guideline-directed medical therapy in this high-risk population. Delivery of optimal care for patients with diabetes and CKD will require collaboration across health care specialties and disciplines.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Alicic RZ, Neumiller JJ, Galindo RJ, et al. Use of Glucose-Lowering Agents in Diabetes and CKD. Kidney Int Rep. 2022. PMID: 36506243. doi:10.1016/j.ekir.2022.09.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。